Vivos Therapeutics (VVOS) Projected to Post Earnings on Tuesday

Posted by Stanley Muller on Aug 11th, 2026

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Vivos Therapeutics to announce earnings of ($0.42) per share and revenue of $5.6330 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 5:00 PM ET.

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) last posted its earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). The business had revenue of $5.14 million during the quarter, compared to analyst estimates of $4.35 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%. On average, analysts expect Vivos Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vivos Therapeutics Stock Performance

VVOS stock opened at $0.32 on Tuesday. The company has a market capitalization of $4.42 million, a P/E ratio of -0.15 and a beta of 6.22. Vivos Therapeutics has a 52-week low of $0.30 and a 52-week high of $5.12. The business has a 50-day simple moving average of $0.48 and a two-hundred day simple moving average of $0.95.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VVOS. HC Wainwright dropped their target price on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a report on Friday, April 17th. Ascendiant Capital Markets increased their price target on Vivos Therapeutics from $3.00 to $3.10 and gave the company a “buy” rating in a research report on Thursday, June 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $2.80.

Get Our Latest Research Report on Vivos Therapeutics

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in shares of Vivos Therapeutics during the 2nd quarter worth $65,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics during the second quarter valued at about $220,000. DRW Securities LLC grew its position in Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares during the period. Finally, Connective Capital Management LLC purchased a new stake in Vivos Therapeutics during the third quarter worth about $620,000. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.